A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Change in ECV; change in BP
研究概览
简要总结
The optimal treatment of drug resistant (defined as BP> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.
详细描述
Following recruitment subjects will have ECV measured by 51Cr-EDTA determination of GFR, with Brochner-Mortensen correction applied. Subjects then receive the following drugs, in a randomised fashion, for a period of four weeks each, with BP & ECV measurement at end of each period: doxazosin GITS (Cardura XL) 4 mg b.d.; frusemide 40 mg b.d.; amiloride 5 mg b.d.; placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BP >140/85
- •3 antihypertensive drugs (ACE/ARB + calcium channel blocker + thiazide diuretic)
排除标准
- •Pregnancy
- •Breast Feeding
- •Unstable heart failure
- •Chronic Liver Disease
- •Creatinine >120 mcmol/L
- •Contraindication to (or intolerance of) drug used in study
- •BP > 180/110
结局指标
主要结局
Change in ECV; change in BP
次要结局
未报告次要终点